April 18, 2018 09:42 AM EDTUpdated 09:53 AM
People
R&D

Glax­o­SmithK­line’s Hal Bar­ron poach­es Genen­tech’s top can­cer drug deal­mak­er for his new R&D team

John Carroll

Editor & Founder

Any­one look­ing for fresh hints about GSK’s up­com­ing move on the can­cer front needs to check out the phar­ma gi­ant’s lat­est hire.

New GSK R …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times